We would love to hear your thoughts about our site and services, please take our survey here.
Fyi https://twitter.com/MylesMcNulty/status/1744678709414490214
Re -post : Courtesy of alextak Linkedin research , Worth another mention.
------------------------------
"Seng-Ho JeonSeng-Ho Jeon CEO & President of Daewoong pharmaceutical " great endorsement of IP potential asset
Affimer technology value .
---------------
"Affimer proteins, based on Stefin A, serve as non-IgG scaffold proteins capable of acting as antagonists or agonists by binding to specific antigens, much like antibodies. We have established cell banks for both DW-MSC and AffyXell, enabling consistent, reproducible, and scalable batch production from a single cell bank.
Our lead pipeline candidate, AFX001, is designed to inhibit CD40-CD40L signaling by binding to CD40L and blocking the interaction through the secretion of an anti-CD40L antagonistic Affimer. CD40-CD40L signaling plays a pivotal role in T cell activation, T cell-mediated B cell activation/differentiation, and immune responses involving antigen-presenting cells (APCs). Inhibition of T cell and B cell activation through CD40-CD40L signaling suppression offers therapeutic potential for conditions like GvHD and various autoimmune diseases, including systemic lupus erythematosus, type 1 diabetes mellitus, multiple sclerosis, and rheumatoid arthritis.
Excitingly, we have demonstrated AFX001's outstanding efficacy compared to un-transduced MSCs using a humanized Graft versus Host Disease (GvHD) mouse model. Furthermore, AFX001 exhibits comparable efficacy to a pre-clinically verified anti-CD40L antibody.
We recently concluded a smooth pre-IND meeting with the US FDA, and we are on track to initiate patient-targeted clinical trials in the second half of this year. We are ready to manufacture GMP batch for the clinical trials with the established GMP-grade Master Cell Bank (MCB) and Working Cell Bank (WCB). "
AffyXell website communication translation - making sure they recruit the right people - made me chuckle - "with more competent people."
----------------------
"Notice of Delay in Announcement of Recruitment Document Screening for the Second Half of 2023
date 2023-12-27 09:56:52
Kinds28
[Apicell Therapeutics 2023 Recruitment (Drug Planning, Drug Development, R&D) Document Screening Delay]
Regarding the recruitment of Apicell Therapeutics (drug planning, drug development, R&D) in the second half of 2023
The announcement of the successful applicants of the document screening, which was scheduled for the end of the month, was due to the support and interest of many people.
We would like to inform you that it has been postponed by 1 ~ 2 weeks.
We would like to inform you that we have adjusted the presentation schedule in order to be with more competent people.
Thank you for your understanding.
※ Notes
- The announcement of successful applicants will be notified via personal e-mail, and those who fail will be notified separately."
Thanks alextak for sharing -great find .
Has wording on AffyXell Platform website summary wording changed ? --- anyway very positive english translation . .
http://affyxell.com/technology/tech.php
-----------
"AffyXell Platform
Novel Cell & Gene Therapy Platform for Immune-mediated Diseases
'AffyXell', developed by Apicell Therapeutics, is a next-generation cell and gene therapy that introduces the Affimer® gene to DW-MSC, which has the advantage of not losing the characteristics of stem cells for a long time. 'AffyXell' maintains the immune/inflammatory regulation function of stem cells, and it is expected that the efficacy will be superior to that of stem cells developed so far by further strengthening the immune/inflammatory regulation function with Affimer®.
In addition, Affimer®is a substance that acts on specific proteins, which has the advantage of clearly explaining the mechanism of action of AffyXell's therapeutic effect.
AffyXell is based on DW-MSC and can be used on multiple people (allopathic therapy) and can be developed as a ready-made product that can be administered to patients without any operation in hospitals, so it is expected to become a new concept of cell and gene therapy that is completely different from existing stem cell therapies."
------------------
Quite a large Molecular diagnostics market .
"The global molecular diagnostics market size was valued at USD 30.89 billion in 2022 and is expected to decline at a compounded annual rate of -0.4% from 2023 to 2030.
Molecular Diagnostics Market Size And Share Report, 2030
https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market#:~:text=The%20global%20molecular%20diagnostics%20market%20size%20was%20valued,annual%20rate%20of%20-0.4%25%20from%202023%20to%202030.
Might be of interest---appreciate affimers manana to some here but some external coverage from :.
https://benchmarkantibodies.com/
"The Future of Affimers As research into Affimers continues to expand, their versatility and unique properties promise to open new doors in scientific research and biotechnology. Their stability, specificity, and adaptability make them valuable tools for addressing complex biological questions and driving advancements in medical and environmental fields.
In conclusion, Affimers have emerged as a compelling alternative to aptamers in the realm of molecular recognition. These protein-based molecules offer distinct advantages and applications, particularly in the domain of protein-related research. As our understanding of Affimers deepens and their use becomes more widespread, they are poised to play a pivotal role in advancing scientific knowledge and technology."
https://benchmarkantibodies.com/index.php/2023/11/02/affimers-the-rising-stars-in-molecular-recognition/
https://benchmarkantibodies.com/index.php/author/antibodycontrols-com/page/2/
Note Avacta have now deleted
https://avacta.com/terms-conditions 2024-01-04 12:41 +00:00
with a new link
"Terms & Conditions
Download our STANDARD TERMS AND CONDITIONS OF PURCHASE OF GOODS AND SERVICE"
https://avacta.com/terms-conditions/ 0 2024-01-04 16:04 +00:00
https://avacta.com/terms-conditions/
Previous version - seem to have deleted
"Download our CUSTOM SCREENING AFFIMER® PROTEIN RESEARCH AND MATERIALS TERMS AND CONDITIONS"
"Terms & Conditions
Avacta Life Sciences Limited – Affimer product supply terms & conditions
Download our STANDARD TERMS AND CONDITIONS OF PURCHASE OF GOODS AND SERVICES
Download our CUSTOM SCREENING AFFIMER® PROTEIN RESEARCH AND MATERIALS TERMS AND CONDITIONS
https://web.archive.org/web/20230702172447/https://avacta.com/terms-conditions/
Fyi Avacta website update today
https://avacta.com/terms-conditions 2024-01-04 12:41 +00:00
"Avacta Life Sciences Limited – Affimer product supply terms & conditions
"Terms & Conditions
https://avacta.com/terms-conditions/
good morning - yes making progress adding more more leakbot devices
"in the last 14 months lb forsikring has successfully deployed this first order of almost 10,000 devices and have now signed a further order for 7,500 units to be distributed during the first 3 months of 2024."
"“our members have been very engaged with leakbot so far, with take up rates exceeding our expectations,” l****n added.
“we're looking forward to providing more members with the added value of a leakbot.”
according to ondo, the use of the plug in devices can reduce the cost of water damage by up to 70%, with such damage the main cause of home insurance claims.
“this new order shows the commitment forsikring has to distributing leakbot to more of their members, following the excellent take up rates demonstrated so far,” ondo chief executive craig foster commented.!"
Glasgow University involved /listed on AVA 3996 poster.
https://avacta.com/wp-content/uploads/2023/10/AVA3996_AACR-2023.pdf
B2HS2L : Sorry previous link did not check the date : Posted on linkedin one week ago .
Coris obviously still offer the product .
https://www.globenewswire.com/news-release/2023/10/25/2766265/0/en/Rapid-Influenza-Diagnostic-Tests-Market-Worth-Nearly-2-Billion-Globally-by-2030-Exclusive-Report-by-The-Insight-Partners.html
Rapid Influenza Diagnostic Tests Market Report | Demand & Trends 2030
Coverage: Rapid Influenza Diagnostic Tests Market covers analysis By Test Type (Influenza A Tests, Influenza B Test, and Influenza A+B Test); Sample Type (Nasal Swab, Throat Swab, Nasopharyngeal Swab, and Others); Technology [Immunochromatographic Assays, Immunofluorescence Assays, and Nucleic Acid Amplification Test (NAAT)]; End User (Hospitals and Clinics, Diagnostic Centers, Nursing Homes, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
PUBLICATION MONTH : JAN 2024
"
Excellent ReportView company: Excellent Report
6 followers
1w •
Follow
🌎 The global rapid influenza diagnostic test market is growing at a CAGR of 9.8% during 2022–2030.
#market #marketanalysis #marketreport #researchanddevelopment #marketshare #marketsize #share #development #newreport #newrelease #business #size #share #forecast
#australia #northamerica #asiapacific #middleeast #latinamerica #unitedstates #unitedkingdom #india #japan #russia #china #saudiarabia #uae
👉 Major players included in the report are -
· Diasorin S.p.A
· Becton Dickenson
· Becton, Dickinson and Company
· SA Scientific, LTD
· CORIS BIOCONCEPT
· Meridian Bioscience Inc.
· Analytik Jena
· Quidel
· Abbott
· Princeton BioMeditech Corporation
· Roche
Still early days for Avacta Diagnostic acquisitions , could generate some cash for Avacta .
FYI "Rapid Influenza Diagnostic Tests Market Worth Nearly $2 Billion, Globally, by 2030"
https://www.zionmarketresearch.com/report/rapid-influenza-diagnostic-tests-market
https://www.corisbio.com/products/flu-a-flu-b-rt-lamp
Thanks Hurst10 - Can delete PB from my favourites : Lilly quite a good replacement though to follow .
https://www.lilly.com/news
FYI : https://www.linkedin.com/posts/coris-bioconcept_amr-activity-7143626934537637888-Cxoy
----------------
CORIS BIOCONCEPT
2,324 followers2,324 followers
20h • 20h •
Follow
Coris BioConcept will attend #ArabHealth 2024 in Dubai.
You can meet us at booth Z2A59 (Wallonia Pavilion) from Jan. 29 to Feb 1. and discover our rapid tests range to detect #amr #antimicrobial #resistance. If you want to discuss potential partnerships, send an e-mail to Sales@corisbio.com
-----------
More than ever keeping the fight against #amr is core to our Research & Development.
View organization page for Antimicrobial Resistance Fighter Coalition
Antimicrobial Resistance Fighter Coalition
13,331 followers
1w
According to a recent study by the European Centre for Disease Prevention and Control, superbugs cause more than 30,000 deaths each year in Europe alone.
To put it into perspective, that's equivalent to the number of passengers on 10 medium-sized cruise ships.
This alarming statistic highlights the crucial importance of responsible antibiotic use and the urgent need for global cooperation in the fight against antimicrobial resistance.
Let's all exercise responsible antibiotic use. Learn more about what you can do to help: https://bit.ly/3CLUnhF "
Wyn the master wordsmith strikes again "If everybody wants to be all over this then why has the SP the same value over the last 3 years, almost to the penny?"
Looking at the 5 year chart AVCT has offered an ideal opportunity for trading experts like yourself .
https://www.google.com/finance/quote/AVCT:LON?window=5Y
Using your RSI techinical chart signals & 45 years expertise , the SP surely is your friend , plenty of opportunities for you to trade the SP & take profit over the years . As you like to remind us on a daily basis .
So Why , Why , Why , are you so bothered about the actual company . Unless of course in reality you are are not so good as you pretend to be at trading and just want the rest of us , to be as miserable as you .
--------------------------------
P.S. Avacta Asset /IP value will prevail - it is indeed all about the science working -not the current SP .
Have a nice day .
Had a listen to Charles Archer he likes Avacta but very high level explaining the detail .
https://www.youtube.com/watch?v=hwxocmNJACk
Thanks for sharing Jigger_1 : Tremendous progress made , think CEO mentioned 90k Leakbot devices installed as of today , still huge potential to increase that number many times over . Asset IP value will come from recurring annual revenues , could be a very exciting 2024 . Nice stock to hold .
Have a great Xmas & Happy New Year everyone .